在少数情况下，医生可能会因为严重的医学问题比如肿瘤或致命感染而让移植受者停用免疫抑制药物。
In rare cases, a physician may stop a transplant recipient's immunosuppressive drugs because of a serious medical problem such as cancer or life-threatening infection.
实验室中以患乳腺癌的老鼠为试验对象，研究者发现联合用药可以抑制癌症干细胞，而癌症干细胞是肿瘤扩增的驱动因素。
In lab tests using mice with breast cancer, researchers found that the drug combination suppressed the cancer stem cells thought to drive tumor progression.
PTK787因其对肿瘤抑制的出色疗效、口服生物利用度高等特点而成为VEGF受体酪氨酸激酶抑制剂中的佼佼者。
PTK787 is the most promising VEGF receptor- tyrosine kinase inhibitor in pipeline because of its potency in tumor inhibition and oral bioavailability.
UCSD研究者也对丢失肿瘤抑制基因的小鼠进行研究。肿瘤抑制基因可以阻止细胞生长。
The UCSD researchers also studied mice that were missing a tumor suppressor gene, which is a gene that ACTS to prevent cell growth.
针对NOS、COX或两者的选择性抑制剂为血液系统恶性肿瘤的治疗提供了新的线索。
The selective inhibitors of NOS, COX, or the both may provide a new approach for the treatment of hematological malignancies.
当Thompson开始研究这个基因时，他发现RTVP - 1基因是肿瘤抑制基因p53的靶基因，p 53是前列腺癌及其他癌症细胞活性的最主要控制者。
As Thompson began to study the gene, he found that it was a target for a tumor suppressor gene called p53, which is a major controller of cell activity in prostate and other cancers.
结论IL12、IL2基因治疗可抑制小鼠肝癌H 2 2皮下移植瘤的生长，提高机体的抗肿瘤免疫应答，两者联合运用可产生协同效应。
Conclusion Both IL 2 and IL 12 are able to inhibit the growth of mice H22 hepatocellular carcinoma grafted subcutaneously and induce the host anti tumor immune response efficiently.
实体器官移植受者的免疫抑制与移植后的新发恶性肿瘤的危险有很大的相关性；
Immunosuppression in solid-organ recipients is associated with a greater risk of denovo malignancy after transplantation;
实体器官移植受者的免疫抑制与移植后的新发恶性肿瘤的危险有很大的相关性；
Immunosuppression in solid-organ recipients is associated with a greater risk of denovo malignancy after transplantation;
应用推荐